Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
US Department of Justice
Dow
Queensland Health
Cantor Fitzgerald
Farmers Insurance
Cerilliant
Healthtrust
Merck

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOXAPINE

« Back to Dashboard

Clinical Trials for Loxapine

Trial ID Title Status Sponsor Phase Summary
NCT00122733 Loxapine and Weaning From Ventilator Completed Assistance Publique - Hôpitaux de Paris N/A Patients may be very agitated during the weaning period from mechanical ventilation. Administration of loxapine, a neuroleptic that does not notably affect ventilatory drive, may help in obtaining an adequate level of cooperation and, therefore, in reducing the duration of mechanical ventilation.
NCT00290082 Randomized Double-blind Trial of Midazolam and Loxapine in Agitated Patients Terminated University Hospital, Rouen Phase 3 Neuroleptics are used since a long time in the management of severely agitated patients. Loxapine is routinely used in our country, with, to our knowledge no severe adverse event reported, in this indication. However, recently, benzodiazepines have appeared interesting in agitated patients, with the use of midazolam. The aim of this study is to compare midazolam to loxapine in the treatment of severe agitated patients admitted in the emergency department.
NCT00369577 StaccatoTM Loxapine for Inhalation in Schizophrenic Patients With Agitation. Completed Alexza Pharmaceuticals, Inc. Phase 2 The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients. The study will be conducted in 120 agitated schizophrenic patients - either newly admitted to a hospital setting or a research unit for acute agitation or already in hospital for chronic underlying conditions. Patients meeting entry criteria will be randomized to one of two doses of Staccato Loxapine or to Staccato Placebo. Following administration of study drug, assessment of agitation state will be conducted at serial time points using standard agitation scales over a 24 hour period.
NCT00444028 Staccato® Loxapine for Inhalation in Schizophrenia Completed Alexza Pharmaceuticals, Inc. Phase 1 Staccato Loxapine is being developed for the treatment of acute agitation in patients with schizophrenia. A 50 patient, dose escalation Phase I clinical trial was completed in November 2005.
NCT00489476 Staccato® Loxapine for Inhalation in Patients With Migraine Headache Completed Alexza Pharmaceuticals, Inc. Phase 2 The objective of this trial is to assess the efficacy and safety of Staccato Loxapine in patients with migraine headache with or without aura in a clinical setting.
NCT00555412 Staccato Loxapine Multidose PK Completed Atlanta Center for Medical Research Phase 1 The objectives of this trial are to assess the safety, tolerability, and pharmacokinetics of multiple inhaled doses of Staccato Loxapine.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Loxapine

Condition Name

Condition Name for Loxapine
Intervention Trials
Schizophrenia 4
Healthy 3
Bipolar Disorder 2
Obesity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Loxapine
Intervention Trials
Psychomotor Agitation 8
Schizophrenia 4
Disease 3
Bipolar Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Loxapine

Trials by Country

Trials by Country for Loxapine
Location Trials
United States 44
France 4
Canada 2
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Loxapine
Location Trials
Georgia 5
California 4
Indiana 4
Ohio 3
Washington 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Loxapine

Clinical Trial Phase

Clinical Trial Phase for Loxapine
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 5
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Loxapine
Clinical Trial Phase Trials
Completed 17
Recruiting 3
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Loxapine

Sponsor Name

Sponsor Name for Loxapine
Sponsor Trials
Alexza Pharmaceuticals, Inc. 12
Assistance Publique - Hôpitaux de Paris 2
Richard Hall 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Loxapine
Sponsor Trials
Industry 15
Other 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKinsey
Daiichi Sankyo
Merck
Covington
Healthtrust
Argus Health
Dow
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.